BEATBio Therapeutics announces publication of their milestone paper in the European Journal of Heart failure - BB-R12 Provides Significant Improvement in Cardiac Function in Heart Failure Study -also published in Business Wire June 4, 2025
Dr. Carter was executive vice president and chief scientific officer of Targeted Genetics Corporation from 1992 to 2008. He spent 22 years at the National Institutes of Health (NIH), leading its Laboratory of Molecular and Cellular Biology from 1982 to 1992.
Dr. Murry is scientific co-founder and chair of the Scientific Advisory Board. At the University of Washington, he is a professor of pathology, bioengineering and medicine/cardiology and directs the Center for Cardiovascular Biology.
BEAT BioTherapeutics Corp. (BEATBio) is developing BB-R12, a biological therapy for treating heart failure. The page cites World Health Organization data that cardiovascular disease accounts for 29% of deaths worldwide and says about 6 million Americans have heart failure.
BEAT Biotherapeutics Corp. (BEATBio) is developing BB-R12, a gene therapy for treating heart failure. The page says about 26 million people worldwide have heart failure and that new therapies are needed to address it.
